[2010/12/07 United Evening News] American Society of Hematology (ASH) is currently being held at the annual meeting in Orlando, blood cancer physicians around the world gathered, the International Myeloma Foundation (IMF) released the latest treatment for multiple myeloma clinical reports "Revlimid" in as a second-line treatment, the treatment effect carefusion is quite significant, but "Revlimid" hailed by many physicians may be the medical community ever, the most expensive carefusion drugs. It also makes things difficult for physicians, patients and their families to inform future treatment options, whether you want to mention this drug, which has attracted a lot of discussion at the conference. carefusion "Revlimid" line from "Celgene" carefusion biopharmaceutical research and development. National Taiwan University Hospital Hematology physician Hou Xinan The United States also participated in the American Society of Hematology annual meeting, carefusion he noted that patients taking a month "Revlimid" drugs should more than 30 million, carefusion equal to 10,000 a day yuan. Multiple myeloma is the second most common blood cancer worldwide, second only to lymphoma, is expected to affect approximately 750,000 people worldwide, Taiwan about 400 new patients each year. The average 60-70 year old patients, carefusion patients carefusion less than 40 years of age are not many. Hou Xinan noted, "Revlimid" in June this year, the Department of Health to obtain drug licenses, including National Taiwan University, Taipei Mackay carefusion included, a total of 16 major hospitals in the country are participating in this global multi-center clinical trials of drugs, carefusion the drug was observed for the first line and maintenance therapy. "Multiple myeloma is an incurable disease!" CCH Hematology and Oncology, Director Chih-Yuan Chung pointed out that the patients carefusion after diagnosis, must accept a series of chemotherapy, and the use of the drug "thalidomide" inhibit tumor angiogenesis. If the condition continued to deteriorate, treatment failure, "Revlimid" is another option. International clinical display, this drug used in combination with another drug dexamethasone, than alone dexamethasone, can prolong the overall survival of patients about six months. Even "Revlimid" low side effects, for more effective disease control, but the price is too expensive, and sometimes even doctors are not open my mouth, worried carefusion family members and patients know, but increased carefusion psychological burden.
Ding Hao goal of turning ????! (Nokia defeated tribe)
Xie Jin River: Find new faces 2014-08-29 12:03 Taiwan stock bulls in the electronic carefusion newspaper "first exploration investment Week" on 1793. Text / Xie Jin River "to explore investment Week" on 1793 a few days ago, a long-lost contact southern elders suddenly called to ask me the stock, he began to ask me Ding Hao Can buy? I asked him, "how do you know ho Ding ...
Free Nokia Terms aborted drug stocks rebounded new shackles industry, academics hide responsibility to expose the general discussion over months Replies mechanism September 27, 2014 [GAO Jia Jing, Chen Yingxin carefusion Taipei "Nokia terms" thunder, carefusion little rain, due to targeted too, the industry rebounded, scholars do not want to bear weighed charges, the competent authorities in order to "set the terms for specific industries, not showing the truth ...
Dalin sea shareholder backing, Jane Feng Ren shares at 04:11 on September 17, 2014 Duhui Rong Xing upcoming Login Liansheng medicine cabinet in the 19th, in addition to 王长怡, Wang Ruiyu two famous women, in fact, the management team and shareholder backing is not small, heavy sea-level celebrities Lin, UMC chairman of Hong Jiacong and Forepi founder Jane Feng Ren also have to participate a coffee, let Liansheng drug did not ...
Where to find the way out to see how Taiwan's biotechnology development? After Nokia event, let us wake up to the biotech drug development is not only time consuming, carefusion but also a high-risk business, of course, is also a high profit! Investors before investing in biotechnology should look at how to stop listening to? Wen. Chen Yiting photography. Zheng Wei Qi two years hottest emerging industries, non-biotech industry must go! She is the star of the government touted the industry, in 2008 the legislature passed "...
Professor: Total global rare cases up to 1680 万 amazing Chinese patients 12 September 2014 07:45:19 Author: China Youth Daily Source: China Youth Daily recently, public event called "bucket challenges" in the community caused carefusion broad participation, aims to call attention called ALS (amyotrophic lateral ...
Business Times: 14 stalls biotech stocks reassert Treasures 2012-07-22 07:27:31 biotech exhibition will start on the 26th, the exhibition is only three days, there are nearly 500 companies, more than 1,000 booths, record high record; addition this year will be added on both sides of the biotech area, plus medical CCP will be included as a biotech focus 二五 plan to attract corporate focus, Japan (41 ...
2014 (991) September (120) 29/09 (10) 27/09 (31) 21/09 (9) 17/09 (10) 12/09 (24) 06/09 ( 7) 03/09 (8) 01/09 (21) August (133) 29/08 (18) 25/08 (21) 22/08 (23) 21/08 (6) 16/08 (21) 12/08 (17) 11/08 (8) 10/08 (3) 01/08 (16) July (74) 30/07 (21) 23/07 (2) 22/07 (8) 16/07 (5) 14/07 (14) 12/07 (8) 08/07 (9) 05/07 (7) June (74) 28/06 (17) 25/06 (4) 20/06 (12) 16/06 (9) 11/06 (12) 09/06 (4) 06/06 (16) May (82) 31/05 (11) 27/05 (16) 20/05 (8) 14/05 (23) 12/05 (13) 01/05 (11) April (136 ) 30/04 (17) 29/04 (14) 21/04 (17) 20/04 (4) 15/04 (19) 10/04 (26) 03/04 (31) 02/04 (8) March (105) 28/03 (15) 25/03 (21) 24/03 (6) 18/03 (3) 16/03 (6) 15 / 03 (7) 13/03 (23) 10/03 (24) February (119) 27/02 (6) 26/02 (20) 21/02 (7) 20/02 (6 ) 19/02 (8) 18/02 (14) 17/02 (8) 15/02 (21) 08/02 (10) 06/02 (19) January (148) 28 / 01 (25) 20/01 (36) 14/01 (18) 08/01 (21) 02/01 (48) 2013 (3067) December (158) 25/12 (18) 24/12 (8) 23/12 (21) 19/12 (16) 16/12 (38) 09/12 (28) 03/12 (11) 02/12 (18) November (186
No comments:
Post a Comment